Hopes of using chloroquine as a promising compound for reducing the immune system activation and inflammation caused by chronic HIV infection seem to have been dashed. Studies show it to be only moderately effective in patients on antiretroviral therapy and so of much less clinical potential than originally thought. Chloroquine is a Toll-like receptor inhibitor and has been tested in a clinical trial with two groups of HIV-infected patients on or off ART with either 250 milligrams of oral chloroquine or placebo for 12 weeks in a crossover study design. The negative result has a positive side in that now research efforts can be deployed to focus on developing alternative approaches.
Chloroquine, less effective in HIV